Quick Answer
UNITED THERAPEUTICS Corp reported Research And Development Expense of $550.00 million for the year ending 2025.
- UNITED THERAPEUTICS Corp showed an increase of +14.3% in Research And Development Expense from 2024 to 2025.
- This data is from UNITED THERAPEUTICS Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2009: $28.65 million | Q3 2009: $31.55 million | Q1 2010: $34.87 million | Q2 2010: $28.59 million | Q3 2010: $40.34 million | Q1 2011: $47.71 million | Q2 2011: $24.24 million | Q3 2011: $59.43 million | Q1 2012: $33.66 million | Q2 2012: $37.10 million | Q3 2012: $65.16 million | Q1 2013: $50.43 million | Q2 2013: $54.62 million | Q3 2013: $72.75 million | Q1 2014: $12.45 million | Q2 2014: $39.74 million | Q3 2014: $118.88 million | Q1 2015: $110.21 million | Q2 2015: $49.41 million | Q3 2015: $9.60 million | Q3 2016: $45.90 million | Q1 2018: $35.70 million | Q2 2018: $82.30 million | Q3 2018: $101.10 million | Q1 2019: $897.40 million | Q2 2019: $85.90 million | Q3 2019: $85.70 million | Q1 2020: $73.20 million | Q2 2020: $89.70 million | Q3 2020: $68.70 million | Q1 2021: $303.70 million | Q2 2021: $74.30 million | Q3 2021: $79.20 million | Q1 2022: $69.00 million | Q2 2022: $93.90 million | Q3 2022: $66.10 million | Q1 2023: $82.90 million | Q2 2023: $89.00 million | Q3 2023: $84.70 million | Q1 2024: $104.10 million | Q2 2024: $139.60 million | Q3 2024: $103.50 million | Q1 2025: $149.00 million | Q2 2025: $134.00 million | Q3 2025: $127.50 million.
- Over the full 18 years of available data (2008 to 2025), UNITED THERAPEUTICS Corp's Research And Development Expense has grown by 130.0%.
- Historical annual values: Fiscal year 2025: $550.00 million | Fiscal year 2024: $481.00 million | Fiscal year 2023: $408.00 million | Fiscal year 2022: $322.90 million | Fiscal year 2021: $540.10 million | Fiscal year 2020: $357.70 million | Fiscal year 2019: $1.18 billion | Fiscal year 2018: $357.90 million | Fiscal year 2017: $264.60 million | Fiscal year 2016: $147.60 million | Fiscal year 2015: $245.10 million | Fiscal year 2014: $242.50 million | Fiscal year 2013: $299.35 million | Fiscal year 2012: $173.39 million | Fiscal year 2011: $180.02 million | Fiscal year 2010: $165.31 million | Fiscal year 2009: $120.37 million | Fiscal year 2008: $239.18 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: